Resumen
Definición
Anamnesis y examen
Principales factores de diagnóstico
- history of intensive chemotherapy regimens
- history of radiation therapy to the oral cavity
- history of chemoradiation
- erythema and/or ulceration of oral mucosa
- oral pain
Otros factores de diagnóstico
- intraoral bleeding
- dietary impairment and/or weight loss
- diarrhea
- nausea and/or vomiting
- abdominal pain
- fever
Factores de riesgo
- intensive chemotherapy regimens
- radiation therapy to the oral cavity
- chemoradiation
- genetic polymorphisms in drug metabolic enzymes
- use of targeted therapies and immunotherapies
Pruebas diagnósticas
Primeras pruebas diagnósticas para solicitar
- clinical diagnosis
Pruebas diagnósticas que deben considerarse
- CBC with differential
- blood cultures
- superficial smear of lesion for microscopy
- fungal culture
- viral culture or polymerase chain reaction (PCR)
Algoritmo de tratamiento
undergoing hematopoietic stem cell transplant: preventive measures
receiving bolus fluorouracil: preventive measures
receiving radiation therapy to oral cavity: preventive measures
established oral mucositis
Colaboradores
Autores
Ourania Nicolatou-Galitis, DDS, MSc, DrDent
Dentist
Specialist in Oral Medicine and Oral Oncology
Hospital Dentistry
National & Kapodistrian University of Athens
Athens
Greece
Divulgaciones
ONG has received fees from Angelini pharma to author a review article on oral mucositis and is the cofounder and scientific responsible of mycancer, a startup private company which aims to provide a comprehensive medical platform for cancer patients. ONG is an author of several references cited in this topic.
Nikolaos Tsoukalas, MD, MSc, PhD
Medical Oncologist
Associate Director
Department of Oncology
401 General Military Hospital
Athens
Greece
Divulgaciones
NT declares that he has no competing interests.
Agradecimientos
Professor Ourania Nicolatou-Galitis and Dr Nikolaos Tsoukalas would like to gratefully acknowledge Dr Eleni Arvanitou, who contributed to the updating of this topic, and Dr Rajesh V. Lalla, a previous contributor.
Divulgaciones
EA declares that she has no competing interests. RVL serves as a consultant for Galera Therapeutics, Ingalfarma, Mundipharma and Sucampo Pharma, and has received research funding from Onxeo, Sucampo Pharma, Galera Therapeutics, and Novartis.
Revisores por pares
Michael Brennan, DDS, MHS
Associate Chairman and Oral Medicine Residency Director
Department of Oral Medicine
Carolinas Medical Center
Charlotte
NC
Divulgaciones
MB is an author of a reference cited in this topic. MB is part of the Mucositis Study Group of MASCC/ISOO, and participated in the review of mucositis.
Maria Michelagnoli, MB ChB, MD, FRCPCH
Consultant Pediatric and Adolescent Oncologist
University College London Hospitals
London
UK
Divulgaciones
MM declares that she has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
Referencias
Artículos principales
Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020 Oct 1;126(19):4423-31.Texto completo Resumen
Peterson DE, Boers-Doets CB, Bensadoun RJ, et al; ESMO Guidelines Committee. Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2015 Sep;26(suppl 5):v139-51.Texto completo Resumen
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
Diferenciales
- Oral candidiasis
- Herpes simplex virus infection
- Graft-versus-host disease
Más DiferencialesGuías de práctica clínica
- MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
- Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines
Más Guías de práctica clínica
Inicie sesión o suscríbase para acceder a todo el BMJ Best Practice
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad